{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:51:02Z","timestamp":1776487862408,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82070746"],"award-info":[{"award-number":["No. 82070746"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse events with the administration of rituximab. We herein report two cases of symptomatic hypokalemia after intravenous rituximab administration in our center, to help health professionals consider the possibility of acute hypokalemia after rituximab administration, monitor potassium timely and develop an appropriate treatment plan.<\/jats:p>","DOI":"10.1186\/s12882-023-03079-4","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T18:02:54Z","timestamp":1689703374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypokalemia after rituximab administration in nephrotic syndrome: two case reports"],"prefix":"10.1186","volume":"24","author":[{"given":"Yiyun","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"6","key":"3079_CR1","first-page":"479","volume":"93","author":"C Kodner","year":"2016","unstructured":"Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016;93(6):479\u201385.","journal-title":"Am Fam Physician"},{"issue":"7654","key":"3079_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","volume":"336","author":"RP Hull","year":"2008","unstructured":"Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336(7654):1185\u20139.","journal-title":"BMJ"},{"issue":"4","key":"3079_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","volume":"20","author":"RP Taylor","year":"2008","unstructured":"Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20(4):444\u20139.","journal-title":"Curr Opin Immunol"},{"issue":"25","key":"3079_CR4","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572\u201381.","journal-title":"N Engl J Med"},{"issue":"8","key":"3079_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.autrev.2012.09.002","volume":"12","author":"AG Kattah","year":"2013","unstructured":"Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):854\u20139.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3079_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco P, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69.","journal-title":"Nat Rev Dis Primers"},{"key":"3079_CR7","doi-asserted-by":"crossref","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.Kidney Int, 2021. 100(4s): p.S1-s276.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"3079_CR8","doi-asserted-by":"publisher","first-page":"859419","DOI":"10.3389\/fimmu.2022.859419","volume":"13","author":"M Teisseyre","year":"2022","unstructured":"Teisseyre M, et al. Advances in the management of primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy. Front Immunol. 2022;13:859419.","journal-title":"Front Immunol"},{"issue":"8","key":"3079_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, et al. Efficacy of Rituximab vs Tacrolimus in Pediatric corticosteroid-dependent nephrotic syndrome: a Randomized Clinical Trial. JAMA Pediatr. 2018;172(8):757\u201364.","journal-title":"JAMA Pediatr"},{"issue":"9","key":"3079_CR10","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3079_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","volume":"5","author":"AS Levin","year":"2017","unstructured":"Levin AS, et al. Reactions to Rituximab in an outpatient infusion Center: a 5-Year review. J Allergy Clin Immunol Pract. 2017;5(1):107\u2013113e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"3079_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi PM, et al. Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012;16(4):231.","journal-title":"Crit Care"},{"issue":"8","key":"3079_CR13","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(8):1416\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"9950","key":"3079_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273\u201381.","journal-title":"Lancet"},{"key":"3079_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3389\/fphar.2020.00915","volume":"11","author":"F Guzzi","year":"2020","unstructured":"Guzzi F, et al. Hypokalemia after Rituximab Administration in Steroid-Dependent Nephrotic Syndrome: a Case Report. Front Pharmacol. 2020;11:915.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3079_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","volume":"21","author":"K Shimada","year":"2020","unstructured":"Shimada K, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(4):593\u2013602.","journal-title":"Lancet Oncol"},{"key":"3079_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3389\/fonc.2020.00779","volume":"10","author":"I Verzicco","year":"2020","unstructured":"Verzicco I, et al. Electrolyte Disorders Induced by Antineoplastic Drugs. Front Oncol. 2020;10:779.","journal-title":"Front Oncol"},{"issue":"10","key":"3079_CR18","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1681\/ASN.2007070792","volume":"18","author":"CL Huang","year":"2007","unstructured":"Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3079_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4103\/1008-682X.129133","volume":"16","author":"MN Stein","year":"2014","unstructured":"Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014;16(3):387\u2013400.","journal-title":"Asian J Androl"},{"key":"3079_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","volume":"777","author":"G Liamis","year":"2016","unstructured":"Liamis G, Filippatos TD, Elisaf MS. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol. 2016;777:78\u201387.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"3079_CR21","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s10637-018-0562-4","volume":"36","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss A, et al. Phase ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018;36(5):848\u201359.","journal-title":"Invest New Drugs"},{"issue":"3","key":"3079_CR22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.kint.2016.06.027","volume":"90","author":"KD Jhaveri","year":"2016","unstructured":"Jhaveri KD, et al. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration adverse event reporting system. Kidney Int. 2016;90(3):706\u20137.","journal-title":"Kidney Int"},{"issue":"1","key":"3079_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00280-009-1131-5","volume":"66","author":"Y Cao","year":"2010","unstructured":"Cao Y, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol. 2010;66(1):37\u201342.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"3079_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00424-007-0258-7","volume":"454","author":"J Wang","year":"2007","unstructured":"Wang J, et al. An intermediate-conductance ca(2+)-activated K (+) channel mediates B lymphoma cell cycle progression induced by serum. Pflug Arch: Eur J Physiol. 2007;454(6):945\u201356.","journal-title":"Pflug Arch: Eur J Physiol"},{"issue":"2","key":"3079_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.bbamcr.2011.11.012","volume":"1823","author":"L-H Wang","year":"2012","unstructured":"Wang L-H, et al. Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of Fc\u03b3RIIB receptors. Biochim Biophys Acta. 2012;1823(2):505\u201313.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"3079_CR26","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1016\/j.jid.2018.05.034","volume":"138","author":"F Caillot","year":"2018","unstructured":"Caillot F, et al. Long-term increase of Kcnn4 Potassium Channel Surface expression on B cells in Pemphigus Patients after Rituximab Treatment. J Invest Dermatol. 2018;138(12):2666\u20138.","journal-title":"J Invest Dermatol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03079-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03079-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03079-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T18:03:53Z","timestamp":1689703433000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03079-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3079"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03079-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. The proof of consent to publish from study participant can be requested at any time.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"214"}}